Increasing The Reach: Optimizing Screening For Atrial Fibrillation: The STROKESTOP III StudyShow others and affiliations
2024 (English)In: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 26, no 9, article id euae234Article in journal (Refereed) Published
Abstract [en]
AIM AND HYPOTHESIS: Atrial fibrillation (AF) is the most common type of cardiac arrythmia and is an important risk factor for ischemic stroke. Many cases of AF remain undiagnosed due to its paroxysmal, intermittent, and often asymptomatic nature. Early detection of AF through screening and initiation of treatment with oral anticoagulants (OACs) can prevent stroke, increase life expectancy, and decrease the cost of healthcare for the society. However, participation has been low in previous AF screening studies employing population screening. The aim of this study is to determine whether opportunistic screening is a superior method to increase participation in comparison to population screening. We hypothesize that opportunistic screening will significantly increase participation.
METHODS: In our study, STROKESTOP III, a randomized prospective cohort study, we compare two different methods of AF screening in high-risk individuals: population screening vs. opportunistic screening. Sixteen different primary clinics in Värmland, Sweden, serving 75-76-year-old individuals (n = 2954), will be randomized to either population screening or opportunistic screening. The individuals will be instructed to record ECG for 30 seconds, 3 times daily for two weeks, using a handheld one-lead ECG device. Patients with detected AF will be referred to their primary healthcare physician and offered treatment. The main objective of the study is to determine the rate of participation in opportunistic screening in comparison to population screening.
Place, publisher, year, edition, pages
Oxford University Press, 2024. Vol. 26, no 9, article id euae234
Keywords [en]
Atrial fibrillation, Prevention, Screening, Stroke
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:oru:diva-116181DOI: 10.1093/europace/euae234ISI: 001316032400001PubMedID: 39298681Scopus ID: 2-s2.0-85205263094OAI: oai:DiVA.org:oru-116181DiVA, id: diva2:1899544
Funder
Swedish Heart Lung FoundationVinnova, 2022-03484Swedish Research Council, 2022-01466Region Stockholm
Note
Funding:
The study is funded by the Swedish Heart and Lung foundation, CIMED, Vinnova (grant number 2022-03484), and the Swedish Research Council (grant number 2022-01466). E.S. has received additional funding from the Region Stockholm (clinical researcher appointment).
2024-09-202024-09-202025-02-10Bibliographically approved